Ram Selvaraju, an analyst from H.C. Wainwright, reiterated the Buy rating on Cognition Therapeutics. The associated price target remains the same with $3.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ram Selvaraju has given his Buy rating due to a combination of factors surrounding Cognition Therapeutics’ promising developments with their drug candidate, zervimesine. The company recently completed an end-of-Phase 2 meeting with the FDA, which provided a clearer regulatory pathway for advancing zervimesine in treating Alzheimer’s disease. The anticipated feedback from the FDA is expected to offer significant clarity and potentially serve as a value inflection point, especially if it allows for a 12-month evaluation period and a single functional outcome measure as the primary endpoint.
Additionally, Cognition Therapeutics is making strides in the development of zervimesine for dementia with Lewy bodies, with positive Phase 2 results and a pending application for Breakthrough Therapy Designation. The company’s ongoing efforts, including the expanded access program and the START trial for early Alzheimer’s disease, further support the potential for zervimesine to achieve regulatory success. These strategic advancements and the possibility of receiving Breakthrough Therapy Designation contribute to the positive outlook and the reiterated Buy rating.
According to TipRanks, Selvaraju is a 5-star analyst with an average return of 19.3% and a 51.11% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Cognition Therapeutics, Urogen Pharma, and Abeona Therapeutics.